Schmidt & Clark, LLP | A National Law Firm

FDA Warning: Maternal Use of SSRIs During Pregnancy May Lead to Persistent Pulmonary Hypertension of the Newborn (PPHN)


|


Persistent Pulmonary Hypertension of the Newborn (PPHN) LawsuitThe U.S. Food & Drug Administration has issued a press release warning the public and medical communities that the use of selective serotonin reuptake inhibitor (SSRI) antidepressants by pregnant women may lead to a catastrophic birth defect known as persistent pulmonary hypertension of the newborn (PPHN). Signs and symptoms of antidepressant-induced PPHN may include rapid heart rate, difficulty breathing, and signs of respiratory distress (i.e nostril flaring and grunting). SSRIs associated with PPHN include Paxil, Prozac, Zoloft, Lexapro, Celexa, Wellbutrin, Symbyax and Effexor.

Free Persistent Pulmonary Hypertension of the Newborn (PPHN) Lawsuit Evaluation: If you or a loved one has a child who has been diagnosed with persistent pulmonary hypertension of the newborn (PPHN) after being exposed to an antidepressant medication in the womb, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer of the antidepressant and we can help.

What’s the problem?

December 14, 2011 – Since initially issuing a Public Health Advisory about the link between SSRIs and PPHN in July 2006, the FDA has continued to receive conflicting findings from new studies evaluating this potential risk. The administration has comprehensively reviewed the new reports and concluded that, based on the conflicting nature of the information, it is currently unable to make a conclusive determination as to the association between the maternal use of SSRIs and PPHN. Antidepressant drug labels will be updated to include this new information.

Selective serotonin reuptake inhibitors are FDA-approved prescription medications used to treat depression and other serious psychological conditions. SSRIs are marketed under the following brand names:

PPHN Overview

PPHN is a life-threatening congenital birth defect in which the newborn’s arteries to the lungs remain constricted after delivery, limiting the amount of blood flow to the lungs and oxygen into the bloodstream. Sadly, up to 20% of children with the condition will end up dying even if they receive treatment. Signs and symptoms of antidepressant-induced PPHN may include (but are not limited to):

  • progressive shortness of breath (especially with activity)
  • hyperventilation (breathing harder and faster)
  • fatigue (tiring easily)
  • progressive weakness
  • fainting spells
  • lightheadedness or dizziness
  • coughing up blood
  • progressive cyanosis (blue tinge to lips, hands, and feet)

Do You Have a Persistent Pulmonary Hypertension of the Newborn (PPHN) Lawsuit?

The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in antidepressant birth defect lawsuits. We are handling individual litigation nationwide and currently accepting new PPHN cases in all 50 states.

Free Persistent Pulmonary Hypertension of the Newborn (PPHN) Lawsuit Evaluation: If you or a loved one has a child who has been diagnosed with persistent pulmonary hypertension of the newborn after being exposed to an antidepressant in the womb, you should contact our law firm immediately. You may be entitled to compensation by filing a PPHN suit and we can help.

Attention Attorneys:  Schmidt & Clark considers a referral from another law firm to be one of the greatest compliments. Our law firm has built a reputation for success and accepts a number of case referrals on a regular basis. We do not publish prior verdicts or settlements on our website. If you would like to refer us a case or for us to send you a profile of prior award judgments or average referral fees, please visit the attorney referral section of our website.